

Refractory Metastatic Melanoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/RCA2A663EC24EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: RCA2A663EC24EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Refractory Metastatic Melanoma - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Refractory metastatic melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Refractory Metastatic Melanoma Understanding

Refractory Metastatic Melanoma: Overview

Refractory metastatic melanoma is the neoplasm of the melanocytes (melanin producing cells). Though melanoma is not common but are the most serious type of skin cancer. Melanoma can develop anywhere on the skin, it can also occur in eyes and other parts of body and on very rare occasions in intestine. Metastatic melanoma can invade the lymphatic system and spread. Exact cause of melanoma is still unclear, however the mutation in DNA of melanocyte due to exposure to UV rays, and other environmental factors are likely to be the leading cause for melanomas. Melanomas can affect both sexes equally. Individuals with history of sunburn, weakened immune

system, many moles or unusual moles on the body, excessive exposure to the ultraviolet radiations, and family-history of melanoma are more prone to develop metastatic melanoma.

“Refractory Metastatic Melanoma - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Refractory Metastatic Melanoma pipeline landscape is provided which includes the disease overview and Refractory Metastatic Melanoma treatment guidelines. The assessment part of the report embraces, in depth Refractory Metastatic Melanoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Metastatic Melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Refractory metastatic melanoma R&D. The therapies under development are focused on novel approaches to treat/improve Refractory metastatic melanoma.

Refractory Metastatic Melanoma Emerging Drugs Chapters

This segment of the Refractory metastatic melanoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Refractory metastatic melanoma Emerging Drugs

IMO-2125: Idera Pharmaceuticals

Idera Pharmaceuticals’ new drug candidate, IMO-2125, is an intratumoral injection in development for the treatment of refractory metastatic melanoma from staged II b to IV. The drug has demonstrated good efficacy in its phase I and phase II clinical trials. IMO-2125 is a toll-like receptor agonist that signals the immune system to create and

activate cancer-fighting cells (T-cells) to target solid tumors in refractory melanoma patients.

Linrodostat: Bristol-Myers Squibb

Bristol's "breakthrough" drug Linrodostat is an orally administered drug molecule is currently being evaluated for the treatment of refractory metastatic melanoma and has demonstrated good safety and tolerability in Phase I trials. Linrodostat is an inhibitor of indoleamine 2, 3-deoxygenase 1 (IDO1) with potential immunomodulating and antineoplastic activities.

Further product details are provided in the report.....

Refractory Metastatic Melanoma: Therapeutic Assessment

This segment of the report provides insights about the different Refractory metastatic melanoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Refractory Metastatic Melanoma

There are approx. 10+ key companies which are developing the therapies for Refractory metastatic melanoma. The companies which have their Refractory metastatic melanoma drug candidates in the mid to advanced stage, i.e. phase III include, Idera Pharmaceuticals and others.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Refractory metastatic melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Natural metabolites

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Refractory Metastatic Melanoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Refractory metastatic melanoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Refractory metastatic melanoma drugs.

Refractory Metastatic Melanoma Report Insights

Refractory metastatic melanoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Refractory Metastatic Melanoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Refractory metastatic melanoma drugs?

How many Refractory metastatic melanoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Refractory metastatic melanoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Refractory metastatic melanoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Refractory metastatic melanoma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Idera Pharmaceuticals

Bristol-Myers Squibb

Sunesin Pharmaceuticals

Taiga biotechnologies

BioNtech

Key Products

IMO-2125

Linrodostat

MLN 2480

TBX 3400

BNT 111

Contents

Introduction

Executive Summary

Refractory Metastatic Melanoma: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Refractory Metastatic Melanoma – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Refractory Metastatic Melanoma companies' collaborations, Licensing, Acquisition
-Deal Value Trends

Refractory Metastatic Melanoma Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

IMO-2125: Idera Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Linrodostat: Bristol-Myers Squibb

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Refractory metastatic melanoma Key Companies

Refractory Metastatic Melanoma Key Products

Refractory Metastatic Melanoma- Unmet Needs

Refractory Metastatic Melanoma- Market Drivers and Barriers

Refractory Metastatic Melanoma- Future Perspectives and Conclusion

Refractory Metastatic Melanoma Analyst Views

Refractory Metastatic Melanoma Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Refractory metastatic melanoma

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Refractory metastatic melanoma

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Refractory Metastatic Melanoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/RCA2A663EC24EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RCA2A663EC24EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970